Bortebuzz 3.5mg Injection

Bortebuzz 3.5mg Injection is a chemotherapeutic agent belonging to the class of proteasome inhibitors. It is indicated for the treatment of multiple myeloma and mantle cell lymphoma. This medication is used concomitantly with other chemotherapy agents including pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone or thalidomide in patients with newly diagnosed disease or those ineligible for or having failed autologous haematopoietic stem cell transplantation.

Bortebuzz 3.5mg Injection is contraindicated in patients with known hypersensitivity to bortezomib or any excipient of the formulation. Use is not recommended in patients with severe immunosuppression or active infection; notify your physician of any active infection prior to commencing treatment. This medication is not recommended for paediatric and adolescent patients. Use is contraindicated in patients with hepatitis.

Inform your doctor before treatment initiation if you have gastrointestinal disorders, hepatic impairment, thrombocytopenia, neutropenia, tumour lysis syndrome, neuropathy, cardiac disorders, severe respiratory disease, pulmonary disorders or posterior reversible encephalopathy syndrome. Monitoring of blood counts and hepatic function tests is necessary throughout the treatment course.

Use during pregnancy and lactation is not recommended. Treatment decisions during pregnancy will be made by the physician only when absolutely necessary, as foetal harm cannot be excluded. Effective contraception is recommended during therapy and for 3 months after treatment completion. Inform your physician if you are pregnant or planning pregnancy. Disclose all concomitant medications, including over-the-counter drugs, vitamins and herbal supplements, prior to treatment initiation.

Bortebuzz 3.5mg Injection pricing is subject to variation based on supplier and geographic location.

The Bortebuzz 3.5mg Injection is used in the following: Treatment of multiple myeloma Treatment of mantle cell lymphoma

Bortebuzz 3.5mg Injection works by exerting a toxic effect on cancer cells. It inhibits the 26S proteasome and blocks a major cell signaling pathway. This inhibition of the signaling pathway makes the cancer cells sensitive to chemotherapy. By inhibiting the proteasome, Bortebuzz 3.5mg Injection disrupts the normal process of protein degradation within the cell. This leads to the accumulation of misfolded or damaged proteins, which are toxic to the cell. The accumulation of misfolded proteins triggers a series of cellular responses, including the activation of stress pathways and the induction of apoptosis. This medicine also enhances the build-up of a protein and minimizes cancer cell growth and multiplication.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious side effects of Bortebuzz 3.5mg Injection are: Peripheral neuropathy Hypotension Cardiac toxicity Posterior Reversible Encephalopathy Syndrome (PRES) Tumor Lysis Syndrome Hepatic Toxicity Thrombotic Microangiopathy Common side effects of Bortebuzz 3.5mg Injection are: Loss of appetite Sensitivity, tingling and burning sensation of the skin Nausea, vomiting, and diarrhea Mouth ulcers Constipation Muscle and bone pain Hair loss Fever Reduction in blood cell count Reduced kidney function Shivering Infections Dehydration Stomach problems Difficulty sleeping, anxiety, mood swings, depressed mood